Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trialVanita R. Aroda, J. Hans DeVries, Mads Axelsen et al.|The Lancet Diabetes & Endocrinology|2017Cited by 439
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the <scp>LEADER</scp> randomized trialOfri Mosenzon, Stephen C. Bain, Hiddo J.L. Heerspink et al.|Diabetes Obesity and Metabolism|2020Cited by 24
Author response for "Cardiovascular and renal outcomes by baseline albuminuria status and renal function — results from the <scp>LEADER</scp> randomized trial"Ofri Mosenzon, Itamar Raz, Stephen C. Bain et al.|Unknown|2020Cited by 0